Key Takeaways HOLX will discontinue Fluoroscan InSight FD by Sept. 30, 2025 due to low margins and limited growth.Hologic's Skeletal Health sales rose 62.1% in Q3 on Horizon DXA ramp-up, boosting overall performance.HOLX narrowed the 2025 revenue guidance to $4.081-$4.091B after strong results and easing tariffs.Hologic’s (HOLX) Skeletal Health division has been driving positive contributions ever since the earlier supply challenges began to ease. Sales jumped 62.1% in the third quarter of fiscal 2025, driv ...